Table 2 Baseline characteristics
Variable | No protocol | CPOE protocol | Revised CPOE protocol | P-value | P-value | P-value |
|---|---|---|---|---|---|---|
(n = 91) | (n = 97) | (n = 91) | 1 vs. 2 | 2 vs. 3 | 1 vs. 3 | |
Age, years (mean ± SD) | 50 ± 22 | 51 ± 20 | 49 ± 22 | 0.67 | 0.5 | 0.82 |
Male gender, n (%) | 59 (65) | 59 (61) | 60 (66) | 0.57 | 0.47 | 0.88 |
Vasopressors, n (%) | 52 (59) | 62 (64) | 55 (60) | 0.5 | 0.62 | 0.85 |
Sepsis, n (%) | 32 (35) | 37 (38) | 30 (33) | 0.67 | 0.46 | 0.75 |
BMI (mean ± SD) | 29 ± 9 | 29 ± 7 | 29 ± 16 | 0.94 | 0.92 | 0.97 |
APACHE II (mean ± SD) | 24 ± 9 | 25 ± 10 | 23 ± 8 | 0.45 | 0.13 | 0.47 |
Admission category | ||||||
Medical, n (%) | 19 (21) | 26 (27) | 21 (23) | 0.9641 | 0.54 | 0.57 |
Surgical, n (%) | 29 (32) | 30 (31) | 25 (28) | |||
Trauma, n (%) | 5 (6) | 5 (5) | 9 (10) | |||
Respiratory, n (%) | 5 (6) | 5 (5) | 8 (9) | |||
Cardiovascular, n (%) | 13 (14) | 12 (13) | 15 (17) | |||
Neurological, n (%) | 20 (22) | 19 (20) | 13 (14) | |||
Organ failure indicators | ||||||
PaO2/FiO2 (mean ± SD) | 238 ± 120 | 202 ± 103 | 211 ± 106 | 0.03 | 0.56 | 0.12 |
GCS (mean ± SD) | 10 ± 4 | 11 ± 5 | 9 ± 4 | 0.45 | 0.02 | 0.11 |
Creatinine (mean ± SD) | 120 ± 93 | 151 ± 159 | 120 ± 122 | 0.097 | 0.13 | 0.99 |
Bilirubin (mean ± SD) | 64 ± 93 | 54 ± 66 | 51 ± 85 | 0.37 | 0.85 | 0.34 |
Platelets (mean ± SD) | 200 ± 155 | 199 ± 160 | 215 ± 155 | 0.99 | 0.49 | 0.5 |
INR (mean ± SD) | 1.6 ± 0.7 | 1.8 ± 1.4 | 1.7 ± 0.99 | 0.19 | 0.54 | 0.42 |
Severe chronic illnesses | ||||||
Chronic respiratory disease, n (%) | 8 (9) | 8 (8) | 8 (9) | 0.89 | 0.89 | 1 |
Chronic cardiovascular disease, n (%) | 16 (18) | 25 (26) | 5 (6) | 0.17 | 0.0001 | 0.01 |
Chronic renal disease, n (%) | 10 (11) | 7 (7) | 9 (10) | 0.37 | 0.51 | 0.81 |
Chronic liver disease, n (%) | 10 (11) | 13 (13) | 5 (6) | 0.61 | 0.07 | 0.18 |
Chronic immunosuppression, n (%) | 10 (11) | 16 (17) | 13 (14) | 0.27 | 0.68 | 0.50 |
Risk Groups | ||||||
Risk 1 patients, n (%) | 24 (26) | 24 (25) | 35 (38) | 0.96 | 0.12 | 0.21 |
Risk 2 patients, n (%) | 18 (20) | 19 (20) | 16 (18) | |||
Risk 3 patients, n (%) | 49 (54) | 54 (56) | 40 (44) | |||